Nor-NOHA

<strong>nor-NOHA </strong>_x000D_ <strong>Catalog number:</strong> B2019453_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 296.3_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> RT_x000D_ <strong>Keywords:</strong> 2S-amino-4-[[(hydroxyamino)iminomethyl]amino]-butanoic acid, diacetate Nω-hydroxy-nor-Arginine_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Ng KP, Manjeri A, Lee LM, Chan ZE, Tan CY, Tan QD, Majeed A, Lee KL, Chuah C, Suda T, Ong ST. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target PLoS One. 2018 Oct 11;13(10):e0205254._x000D_ 2: Chauhan S, Nusbaum RJ, Huante MB, Holloway AJ, Endsley MA, Gelman BB, Lisinicchia JG, Endsley JJ. Therapeutic Modulation of Arginase with nor-NOHA Alters Immune Responses in Experimental Mouse Models of Pulmonary Tuberculosis including in the Setting of Human Immunodeficiency Virus (HIV) Co-Infection Trop Med Infect Dis. 2024 Jun 6;9(6):129._x000D_ 3: Reid KM, Tsung A, Kaizu T, Jeyabalan G, Ikeda A, Shao L, Wu G, Murase N, Geller DA. Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA) Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G512-7._x000D_ 4: Xiong M, Chen H, Fan Y, Jin M, Yang D, Chen Y, Zhang Y, Petersen RB, Su H, Peng A, Wang C, Zheng L, Huang K. Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation Theranostics. 2023 Jun 4;13(10):3387-3401._x000D_ 5: Bagnost T, Guillaume YC, Thomassin M, Berthelot A, Demougeot C, André C. Biochromatographic framework for analyzing magnesium chloride salt dependence on nor-NOHA binding to arginase enzyme J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 15;873(1):37-40._x000D_ 6: Li X, Zhu F, He Y, Luo F. [Arginase inhibitor nor-NOHA induces apoptosis and inhibits invasion and migration of HepG2 cells] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Apr;33(4):477-482._x000D_ 7: Bagnost T, Guillaume YC, Thomassin M, Robert JF, Berthelot A, Xicluna A, André C. Immobilization of arginase and its application in an enzymatic chromatographic column: thermodynamic studies of nor-NOHA/arginase binding and role of the reactive histidine residue J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):113-20._x000D_ 8: Ding LY, Chen LM, Wang MZ, Zhang J, Loor JJ, Zhou G, Zhang X, Wang HR. Inhibition of arginase via jugular infusion of N(ω)-hydroxy-nor-l-arginine inhibits casein synthesis in lactating dairy cows J Dairy Sci. 2018 Apr;101(4):3514-3523._x000D_ 9: Abdelkawy KS, Lack K, Elbarbry F. Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):355-370._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32131024">10: Momma TY, Ottaviani JI. Arginase inhibitor, N(ω)-hydroxy-L-norarginine, spontaneously releases biologically active NO-like molecule: Limitations for research applications Free Radic Biol Med. 2020 May 20;152:74-82. </a>_x000D_ _x000D_ <strong>Products Related to nor-NOHA can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>